A small New Mexico land developer with a $145 million market cap is drawing attention not for its short sellers, but for a single investor who keeps buying the dip.
James H. Dahl, a 10% shareholder in AXR, has made nine separate open-market purchases since late February, accumulating over 15,000 shares at prices between $25.44 and $28.17. His net buying over the past 90 days totals roughly 43,000 shares worth approximately $1.07 million. The latest two trades came on April 17 and April 20, with AXR trading around $27.25–$27.66 — just below where the stock closed the week at $27.60. A director also bought 1,765 shares on April 21. The pattern is consistent and deliberate: Dahl steps in whenever the stock softens, and has done so repeatedly across a two-month window spanning different price levels.
The borrow market tells a story of minimal short conviction. Short interest is only 0.89% of the free float — a level too low to make shorting a meaningful narrative here. Borrow availability is extraordinarily loose at nearly 4,000% of short interest, meaning shares are plentiful and there is essentially no squeeze pressure of any kind. Cost to borrow has actually eased sharply over the past month, down roughly 17% to just 0.54% annualised — the cheapest it has been in recent weeks. The ORTEX short score of 30.6 places AXR in the lower half of the short-pressure universe, well away from any crowded-short territory.
The ownership picture reinforces just how tightly held this stock is. With only 41 institutional holders on record, AMREP is firmly in micro-cap territory with a concentrated register. Albert Russo holds 16% of shares, James Dahl now controls over 13% and continues to add, Robotti & Company — a known value-oriented firm — holds nearly 10%, and Bridgeway Capital and Dimensional Fund Advisors each hold smaller positions. Together, the top three holders account for nearly 40% of shares outstanding. That concentration limits liquidity and amplifies the signal value of any insider move.
The sole analyst covering AMREP with a recent action is Freedom Broker, which raised its target from $27 to $30 in March 2026 after cutting it to $23 in December 2025. The current stock price of $27.60 sits between those two data points — above the prior low target but below the current one. Given the obscurity of the coverage and the single-analyst situation, the Street view here is thin. Valuation data is stale, and no options market exists for a name this small, so the usual positioning signals are absent. What's available instead is a straightforward price-action read: AXR is up 6.6% over the past month but gave back roughly 1.5% this week.
The next scheduled earnings event falls on July 24. The last four prints produced moves of +3.6%, -3.0%, -2.2%, and -8.4% on the day — a mixed record with a notable downside outlier in December 2025. With Dahl buying through the current price range and the stock's next catalyst still three months away, the question heading into summer is whether his accumulation pace continues, and whether any other names on the register follow suit.
See the live data behind this article on ORTEX.
Open AXR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
